PROTEKTProspective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin
References in periodicals archive ?
pneumoniae isolates collected at 119 centers in year 6 of PROTEKT US, 2,381 (35.
With the exception of years 3-4, the proportion of isolates harboring erm(B) and mef(A) throughout the 6 years of the PROTEKT US study has trended upward (Figure 2).
2%) was higher than the PROTEKT US study result (8.
Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001-2002.
Key Words: PROTEKT US, resistance, respiratory infections, southern United States, telithromycin
The PROTEKT US (Prospective Resistant Organism Tracking for the Ketolide Telithromycin in the United States) surveillance study is longitudinally monitoring the antimicrobial susceptibility of S.
Macrolide resistance rates for isolates collected during the PROTEKT US study from 2001 to 2002 vary according to region; at a state level, the highest prevalence of pneumococcal macrolide resistance was recorded in Louisiana (48.
PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) is an international, longitudinal surveillance study initiated in 1999 to evaluate the activity of telithromycin, a new ketolide antibacterial drug, against S.
pneumoniae have been identified (84) in over 10,000 pneumococcal isolates screened by the PROTEKT study (10).
Bacteria that cause community- acquired respiratory tract infections (RTIs) are growing increasingly resistant to the commonly used antibiotics penicillin and erythromycin, according to preliminary data reported here today from PROTEKT (Prospective Resistant Organism Tracking for the Ketolide Telithromycin) a new global surveillance study involving 66 laboratories in 20 countries.